Among the results, it was seen that the plasma levels of CCL2 and CX3CL1 were elevated in patients with ACS compared with patients with stable coronary artery disease, and the TC levels in ACS patients of the chemokines CCL2, CCL5, and CX3CL1 were reduced by treatment with colchicine. The gene discussed is CX3CL1; the disease is coronary artery disorder.